Study FVF2425g was a Phase I, open-label, randomized study of three escalating multiple dose regimens of intravitreally administered ranibizumab. Data show that doses of ranibizumab up to 2 mg could be safely given as part of an escalating dose regimen to subjects with subfoveal choroidal neovascularization due to AMD.